No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19

Archive ouverte

Ko, Adrien Chan Sui | Candellier, Alexandre | Mercier, Marie | Joseph, Cedric | Carette, Hortense | Basille, Damien | Lion-Daolio, Sylvie | Devaux, Stephanie | Schmit, Jean-Luc | Lanoix, Jean-Philippe | Andrejak, Claire

Edité par CCSD ; Dove Press ; Taylor & Francis -

International audience. Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 symptoms. A total of 306 discharged patients, including 112 (36.6%) from the ICU, completed a structured face-to-face assessment 4 months after admission. Of these, 193 patients (63.1%) had at least one persistent symptom, mostly dyspnea (38.9%) and asthenia (37.6%). One-hundred and four patients have received corticosteroids. In multivariable adjusted regression analysis, corticosteroid use was not associated with the presence of at least one symptom (OR=1.00, 95% CI: 0.58-1.71, p=0.99) or with the number of persistent symptoms (p=0.74). Corticosteroid use remained ineffective when analyzing the ICU subpopulation separately. Our study suggests that corticosteroid use had no impact on persistent symptoms after COVID-19 in discharged patients.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion